Skip to main content
Top
Published in: Rheumatology International 12/2017

01-12-2017 | Correspondence

In reply to the letter to the Editor, “HAQ score is an independent predictor of sustained remission in patients with rheumatoid arthritis”

Authors: Kyung-Eun Lee, Shin-Seok Lee

Published in: Rheumatology International | Issue 12/2017

Login to get access

Excerpt

Dear Editor, …
Literature
1.
go back to reference Lee KE, Choi SE, Xu H, Kang JH, Park DJ, Lee SS (2017) HAQ score is an independent predictor of sustained remission in patients with rheumatoid arthritis. Rheumatol Int. doi:10.1007/s00296-017-3833-z Lee KE, Choi SE, Xu H, Kang JH, Park DJ, Lee SS (2017) HAQ score is an independent predictor of sustained remission in patients with rheumatoid arthritis. Rheumatol Int. doi:10.​1007/​s00296-017-3833-z
Metadata
Title
In reply to the letter to the Editor, “HAQ score is an independent predictor of sustained remission in patients with rheumatoid arthritis”
Authors
Kyung-Eun Lee
Shin-Seok Lee
Publication date
01-12-2017
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 12/2017
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-017-3851-x

Other articles of this Issue 12/2017

Rheumatology International 12/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.